Radiation-induced optic neuropathy after pencil beam scanning proton therapy for skull-base and head and neck tumours.


Journal

The British journal of radiology
ISSN: 1748-880X
Titre abrégé: Br J Radiol
Pays: England
ID NLM: 0373125

Informations de publication

Date de publication:
Mar 2020
Historique:
pubmed: 20 7 2019
medline: 28 2 2020
entrez: 20 7 2019
Statut: ppublish

Résumé

To assess the radiation-induced optic neuropathy (RION) prevalence, following high dose pencil beam scanning proton therapy (PBSPT) to skull base and head and neck (H&N) tumours. Between 1999 and 2014, 216 adult patients, median age 47 years (range, 18-77), were treated with PBS PT for skull base or H&N malignancies, delivering ≥45 Gy RION was observed in 14 (6.5%) patients at a median time of 13.2 months (range, 4.8-42.6) following PBSPT. Most (92.9%) of RION were symptomatic. Most affected patients (11/14; 79%) developed unilateral toxicity. Grade 4, 3, 2 and 1 toxicity was observed in 10, 2, 1 and 1 patients, respectively. On univariate analyses, age (<70  These data suggest that high-dose PBS PT for skull base and H&N tumours is associated with a low prevalence of RION. Caution should be however exercised when treating elderly/hypertensive patients with tumours abutting the optic apparatus. This is the first study reporting the risk of developing RION following proton therapy with PBS technique, demonstrating the safety of this treatment.

Identifiants

pubmed: 31322969
doi: 10.1259/bjr.20190028
pmc: PMC7066972
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

20190028

Références

Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):865-71
pubmed: 22138457
Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):392-8
pubmed: 11567813
Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):616-623
pubmed: 28011049
Mol Clin Oncol. 2016 May;4(5):868-872
pubmed: 27123298
Br J Ophthalmol. 1969 Nov;53(11):721-48
pubmed: 4982590
Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1070-7
pubmed: 15990010
Radiother Oncol. 2016 Jul;120(1):169-74
pubmed: 27247057
Z Med Phys. 2004;14(3):147-52
pubmed: 15462415
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S10-9
pubmed: 20171502
Trans Ophthalmol Soc U K. 1970;89:125-46
pubmed: 5276645
Med Phys. 2004 Nov;31(11):3150-7
pubmed: 15587667
Ophthalmology. 2012 Apr;119(4):879-80
pubmed: 22472252
Semin Ophthalmol. 2018;33(4):581-588
pubmed: 28704158
Int J Radiat Oncol Biol Phys. 1992;23(1):27-39
pubmed: 1572828
Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):691-702
pubmed: 17161557
Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1601-6
pubmed: 2542198
Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):273-84
pubmed: 9226313
Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1487-92
pubmed: 19345516
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S28-35
pubmed: 20171514
Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):755-63
pubmed: 7960976
Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1363-70
pubmed: 11121635
J Clin Neurosci. 2008 Feb;15(2):95-100
pubmed: 18068989
Phys Med Biol. 2005 Feb 7;50(3):541-61
pubmed: 15773729
Radiother Oncol. 2006 Dec;81(3):243-9
pubmed: 17050017
Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):232-9
pubmed: 17084541

Auteurs

Melpomeni Kountouri (M)

Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, CH-5232, Villigen, Switzerland.

Alessia Pica (A)

Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, CH-5232, Villigen, Switzerland.

Marc Walser (M)

Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, CH-5232, Villigen, Switzerland.

Francesca Albertini (F)

Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, CH-5232, Villigen, Switzerland.

Alessandra Bolsi (A)

Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, CH-5232, Villigen, Switzerland.

Ulrike Kliebsch (U)

Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, CH-5232, Villigen, Switzerland.

Barbara Bachtiary (B)

Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, CH-5232, Villigen, Switzerland.

Christophe Combescure (C)

Service d'Epidemiologie Clinique, Hôpitaux Universitaire de Genève, CH 12011 Geneva, Geneva, Switzerland.

Antony J Lomax (AJ)

Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, CH-5232, Villigen, Switzerland.
Department of Physics, ETH, Zürich, Switzerland.

Ralf Schneider (R)

Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, CH-5232, Villigen, Switzerland.

Damien Charles Weber (DC)

Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, CH-5232, Villigen, Switzerland.
University of Bern, Bern, Switzerland.
University of Zürich, Zürich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH